title: [Medulloblastomas: review].
abstract: BACKGROUND
  The term of "medulloblastoma" refers to cerebellar tumors belonging to the family of primitive neuro-ectodermic tumors (PNET). Medulloblastomas represent 40% of cerebellar tumors, 15 to 20% of brain tumors and the first cause of malignant brain tumors in childhood. Seventy to 80% of cases are diagnosed in children versus 20 to 30% in adults.
  Diagnosis is based on clinical and radiological exams, and proved on pathological analysis in association with molecular biology. Treatment comprises surgery, craniospinal radiotherapy except for children under five years of age and chemotherapy according to age and high-risk criteria. Medulloblastoma is a rare case of a central nervous system tumor which is radio- and chemo-sensitive. Treatment goals are, on one hand, to improve the survival rates and, on the other hand, to avoid late neurocognitive, neuroendocrine and orthopedic side effects related to radiation therapy, notably in children. The prognosis is relatively good, with a five year survival rate over 75% after complete resection of a localized tumor although sequelae may still compromise outcome.
  
  
  CONCLUSIONS
  Management of patients with medulloblastoma implies a multidisciplinary approach combining the contributions of neurosurgery, neuroradiology, pediatric oncology, neuro-oncology and radiotherapy teams.
authors.affiliation: Unité de neuro-oncologie, service de neurologie, CHU hôpital central, 29, avenue de-Lattre-de-Tassigny, 54035 Nancy cedex, France. l.taillandier@chu-nancy.fr
authors.forename: L
authors.initials: L
authors.lastname: Taillandier
authors.forename: M
authors.initials: M
authors.lastname: Blonski
authors.forename: C
authors.initials: C
authors.lastname: Carrie
authors.forename: V
authors.initials: V
authors.lastname: Bernier
authors.forename: F
authors.initials: F
authors.lastname: Bonnetain
authors.forename: F
authors.initials: F
authors.lastname: Bourdeaut
authors.forename: I-C
authors.initials: IC
authors.lastname: Thomas
authors.forename: P
authors.initials: P
authors.lastname: Chastagner
authors.forename: F
authors.initials: F
authors.lastname: Dhermain
authors.forename: F
authors.initials: F
authors.lastname: Doz
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: J
authors.initials: J
authors.lastname: Grill
authors.forename: R
authors.initials: R
authors.lastname: Guillevin
authors.forename: A
authors.initials: A
authors.lastname: Idbaih
authors.forename: A
authors.initials: A
authors.lastname: Jouvet
authors.forename: C
authors.initials: C
authors.lastname: Kerr
authors.forename: F-L
authors.initials: FL
authors.lastname: Donadey
authors.forename: L
authors.initials: L
authors.lastname: Padovani
authors.forename: J
authors.initials: J
authors.lastname: Pallud
authors.forename: M-P
authors.initials: MP
authors.lastname: Sunyach
mesh_terms: D002528:Cerebellar Neoplasms / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D008527:Medulloblastoma / Q000175:diagnosis / Q000628:therapy; D016896:Treatment Outcome